Table 2.
Alterations in gyrA and parC genes of 107 Chinese QRNG isolates.
| Mutation Pattern | Phe. | Amino acid substitution in: | No. of strains (%) | Cip MIC range (μg/mL) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||
| GyrA | ParC | ||||||||||||
|
|
|
||||||||||||
| Ser-91 (TCC) | Ala-92 (GCA) | Asp-95 (GAC) | Ile-97 (ATC) | Gln-102 (CAA) | Asp-86 (GAC) | Ser-87 (AGT) | Ser-88 (TCC) | Glu-91 (GAG) | Leu-106 (TTA) | ||||
| P1 | Cipr | Phe (TTC) | Asn (AAC) | Asn (AAT) | 11 (10.3%) | 1–2 | |||||||
| P2 | Cipr | Phe (TTC) | Asn (AAC) | Lys (AAG) | 5 (4.7%) | 1–2 | |||||||
| P3 | Cipr | Phe (TTC) | Asn (AAC) | Pro (CCC) | 3 (2.8%) | 1–2 | |||||||
| P4 | Cipr | Phe (TTC) | Ala (GCC) | Gly (GGG) | 5 (4.7%) | 1–2 | |||||||
| P5 | Cipr | Phe (TTC) | Ala (GCC) | Asn (AAC) | 11 (10.3%) | 1–2 | |||||||
| P6 | Ciph | Phe (TTC) | Asn (AAC) | Ile (ATT) | 2 (1.8%) | 4–16 | |||||||
| P7 | Ciph | Phe (TTC) | Gly (GGC) | Arg (CGT) | 27 (25.2%) | 4–32 | |||||||
| P8 | Ciph | Phe (TTC) | Ala (GCC) | Arg (CGT) | 16 (15.0%) | 4–32 | |||||||
| P9 | Ciph | Phe (TTC) | Ala (GCC) | Asn (AAC) | 12 (11.2%) | 4–32 | |||||||
| P10 | Ciph | Phe (TTC) | Gly (GGC) | Asn (AAC) | 8 (7.5%) | 4–32 | |||||||
| P11 | Ciph | Phe (TTC) | Ala (GCC) | Arg (CGT) | Ala (GCG) | 1 (0.9%) | 64 | ||||||
| P12 | Cipr | Phe (TTC) | Pro (CCA) | 1 (0.9%) | 12 | ||||||||
| P13 | Ciph | Phe (TTC) | Pro (CCA) | Gly (GGC) | Arg (CGT) | 1 (0.9%) | 32 | ||||||
| P14 | Ciph | Phe (TTC) | Ala (GCC) | Met (ATG) | Pro (CCC) | 1 (0.9%) | 8 | ||||||
| P15 | Ciph | Phe (TTC) | Ala (GCC) | His (CAC) | Asn (AAC) | 1 (0.9%) | 16 | ||||||
| P16 | Ciph | Phe (TTC) | Ala (GCC) | Arg (CGT) | Ile (ATA) | 1 (0.9%) | 32 | ||||||
Abbreviations: Cip, ciprofloxacin; r, resistant; h, high-level resistant; Phe, Phenotype.